Study of the Pronostic Impact of Immunohistochemical, Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma.

Study of the Pronostic Impact of Immunohistochemical, Histological, Radiological and Molecular Factors in Patients With Primary Central Nervous System Lymphoma

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05347511

Enrollment

Registered

2022-04-26

Start date

2022-04-20

Completion date

2022-09-01

Last updated

2022-04-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Rare Disease With Poor Outcome

Brief summary

Primary Central Nervous System Lymphoma (PCNSL) have a specific mutational profile in comparison to systemic diffuse large cells lymphoma (DLBCLs) that can be related to the expression of immunohistochemical markers as cyclon, NPM1, CD30, and P53 which could be predictive factor for prognosis and/or chemotherapy response. The main objective of this study is to identify new prognostic factors and new potential therapeutic targets. The secondary objectives are to correlate the histological, the radiological and the clinical's informations of these patients.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

21 Years to No maximum

Healthy volunteers

Inclusion criteria

* PCNSL diagnosed between January 2011 and December 2019, without regard to the clinical outcome. * Age \> 18

Exclusion criteria

* Systemic DLBCL

Design outcomes

Primary

Measure	Time frame	Description
correlation between the survival and the expression of Cyclon, NPM1 and CD30.	17/10/2022	kaplan meyer

Secondary

Measure	Time frame	Description
the correlation between the molecular abnormalities and the expression of Cyclon, NPM1 and CD30	17/10/2022	mutational signature

Outcome results